

RESOLUTION AUTHORIZING ENTRY OF PARTICIPATION AGREEMENTS
IN PARTIAL SETTLEMENT OF THE NATIONAL PRESCRIPTION OPIATE
LITIGATION AND ENTRY OF STATE LOCAL GOVERNMENT INTRASTATE
AGREEMENT CONCERNING ALLOCATION OF SETTLEMENT PROCEEDS

WHEREAS, the **INSERT NAME OF LOCAL GOVERNMENT** filed a lawsuit to
address the public nuisance that is the Opioid Epidemic;

AND WHEREAS the following entities:

1. Alvogen Inc.
2. Amneal Pharmaceuticals, Inc.
3. Apotex Inc.
4. Hikma Pharmaceuticals USA, Inc.
5. Indivior Inc.
6. Mylan Pharmaceuticals Inc.
7. Sun Pharmaceutical Industries, Inc. and
8. Zydus Pharmaceuticals, Inc.

(“Settling Defendants”) have negotiated proposed national settlement agreements
 (“Proposed Settlements”) with the State Attorneys General, and a Plaintiff Executive
 Committee-designated negotiating committee that represents approximately 4,000
 local governments that have brought lawsuits similar to **INSERT NAME OF
 LOCAL GOVERNMENT**’s lawsuit;

AND WHEREAS the Proposed Settlements contain significant equitable and
 monetary relief, including:

1. An agreement to pay (a) \$18,680,162 in a single year by Alvogen Inc.; (b)
 \$71,751,010 over ten years by Amneal Pharmaceuticals, Inc.; (c) \$63,682,369
 in a single year by Apotex Inc.; (d) \$95,818,293 over one to four years by
 Hikma Pharmaceuticals USA, Inc.; (e) \$38,022,450 over four years by
 Indivior Inc.; (f) \$284,447,916 over nine years by Mylan Pharmaceuticals
 Inc.; (g) \$30,992,087 over one to four years by Sun Pharmaceutical Industries,
 Inc.; and (h) \$14,859,220 in a single year by Zydus Pharmaceuticals, Inc. The

bulk of each of these payments will be dedicated to funding abatement and prevention strategies associated with the opioids public nuisance;

2. In addition to these abatement payments, several of the settlements allow states to receive free pharmaceutical products or cash in lieu of this product.
3. Additionally, seven of the companies (not including Indivior) are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders.
4. Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.

AND WHEREAS **INSERT NAME OF LOCAL GOVERNMENT** previously executed Participation Agreements for the Distributor and Janssen Settlements, as well as the Teva, Allergan, CVS, Walmart, and Walgreens Settlements, which have conferred and continue to confer valuable benefits;

AND WHEREAS **INSERT NAME OF LOCAL GOVERNMENT** desires to enter into an allocation method which allocates settlement funds from the Settling Defendants on a 50/50 basis to:

1. Local Governments who have elected to participate in the settlements with the Settling Defendants; and
2. the State of Michigan.

NOW THEREFORE, **INSERT NAME OF LOCAL GOVERNMENT** authorizes the execution of Participation Agreements for the Master Settlement Agreements with: (1) Alvogen Inc.; (2) Amneal Pharmaceuticals, Inc.; (3) Apotex Inc.; (4) Hikma Pharmaceuticals USA, Inc.; (5) Indivior Inc.; (6) Mylan Pharmaceuticals Inc.; (7) Sun Pharmaceutical Industries, Inc.; and (8) Zydus Pharmaceuticals, Inc., each of which are listed and available to the public at <https://nationalopioidsettlement.com/additional-settlements/>. Specimen copies of the material terms of the participation agreements are attached in one combined PDF as Exhibit A to this resolution.

INSERT NAME OF LOCAL GOVERNMENT also authorizes the execution of a new Michigan State-Subdivision Agreement for Allocation of Opioid Settlement Agreements substantially similar to the proposed agreement attached as Exhibit B to this resolution.